Pathstone Family Office’s Cognition Therapeutics CGTX Stock Holding History

Pathstone Family Office’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$3.18M	Hold	2,205,377	–	–	0.02%	373
2023 Q2	$4.04M	Sell	2,205,377 -5,000	-0.2%	-$10.6K	0.06%	195
2023 Q1	$4.38M	Sell	2,210,377 -2,210,377	-50%	-$4.21M	0.07%	163
2022 Q4	$212	Hold	4,420,754	–	–	﹤0.01%	1489
2022 Q3	$8.4M	Buy	4,420,754 +2,210,377	+100%	+$4.6M	0.08%	153
2022 Q2	$4.66M	Buy	+2,210,377	New	+$5.71M	0.1%	110

Other funds holding CGTX

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

PWM

Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Pathstone Family Office's CGTX Position: Q3 2023 in Review

Pathstone Family Office held its Cognition Therapeutics (CGTX) position steady in Q3 2023 at 2,205,377 shares worth $3.18M. The position accounts for 0.02% of the portfolio, ranked #373.

Pathstone Family Office first reported a position in CGTX in Q2 2022 and has held it in 6 quarters since. The position peaked at $8.4M in Q3 2022. 36 funds tracked by Wall St. Rank hold CGTX as of Q3 2023.

Pathstone Family Office held 2,205,377 shares of Cognition Therapeutics worth $3.18M as of Q3 2023.
Pathstone Family Office left its Cognition Therapeutics share count unchanged in Q3 2023.
Cognition Therapeutics made up 0.02% of Pathstone Family Office's portfolio in Q3 2023, its #373 holding.
Pathstone Family Office first reported a position in Cognition Therapeutics in Q2 2022 and has held it in 6 quarters since.
Pathstone Family Office's Cognition Therapeutics position peaked at $8.4M in Q3 2022.
36 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.